AIVita Biomedika Indonesia

AIVita Biomedika Indonesia is a biotechnology company that serves as the Indonesian subsidiary of the California-based AIVita Biomedical. The company is primarily focused on the development of personalized immunotherapy and regenerative medicine, utilizing a proprietary dendritic cell platform. It gained significant prominence for its role in developing Vaksin Nusantara, an autologous dendritic cell vaccine for COVID-19, in collaboration with local Indonesian health authorities. Beyond infectious diseases, the company works on bringing advanced cell therapies for various cancers, including glioblastoma and melanoma, to the Indonesian healthcare market. Their operations include specialized laboratory facilities in Jakarta capable of processing patient-specific cell treatments. The company aims to localize high-tech biomedical solutions to address unmet medical needs in Southeast Asia.